NCT04062266View on ClinicalTrials.gov

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2030

Conditions
Acute Myeloid Leukemia in RemissionFLT3 Gene MutationHematologic and Lymphocytic DisorderAcute Myeloid LeukemiaMinimal Residual Disease PersistenceTherapy-Related Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given SC or IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER